** Shares of healthcare company Accolade ACCD.O more than double to $6.90 premarket

** ACCD says it has entered into an agreement where Transcarent will acquire it for $7.03 per share in cash, representing an equity value of about $621 mln

** Transaction is expected to close in Q2 2025; upon completion, ACCD will become privately held company

** Deal represents a premium of ~110% over ACCD's last closing price

** Transcarent uses generative AI to provide health information, while also providing personalized health guidance and on-demand care

** ACCD provides personalized, technology-enabled solutions to help people understand and utilize healthcare system and workplace benefits

** Deal will "create a more personalized healthcare experience for people while improving outcomes and driving down costs," ACCD says

** Up to last close, ACCD had fallen 69.5% in the past 12 months

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))